Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics (ANIK)
NASDAQ:ANIK
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.26Last Year’s EPS
0.17Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 09, 2025
|% Change Since: -23.00%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Anika. While there were significant achievements in the commercial channel and progress in pipeline programs, there were notable challenges in the OEM channel, manufacturing inefficiencies, and an overall decline in revenue and adjusted EBITDA.Company Guidance
During Anika's first quarter earnings call for fiscal year 2025, the company provided guidance on various financial metrics and strategic initiatives. Total revenue for the quarter was reported at $26.2 million, reflecting a 10% year-over-year decline, primarily due to pricing challenges in the OEM channel. However, the commercial channel showed strong performance with an 18% increase in revenue, driven by 33% growth in the regenerative solutions portfolio. The company experienced ongoing pricing pressures in the domestic OA Pain Market, resulting in a 23% decrease in OEM channel revenue. Despite these challenges, Anika's operating expenses were reduced by 12% year-over-year, aiding in partially offsetting the impact of decreased high-margin sales. The company maintained its commercial revenue guidance between $47 million and $49.5 million for the year, but adjusted its OEM guidance to a range of $62 million to $65 million, representing a 16% to 20% decline. Adjusted EBITDA guidance was revised to a range of negative 3% to positive 3%, reflecting manufacturing challenges and updated pricing assumptions. Anika remains focused on advancing its strategic initiatives, including the anticipated U.S. approvals of Hyalofast and Cingal, and continues to expand its Integrity platform to drive future growth.Commercial Channel Revenue Growth
The commercial channel revenue increased by 18% year-over-year to $11.3 million, driven by Integrity and international OA pain management growth.
Regenerative Solutions Growth
The regenerative solutions portfolio, particularly Integrity, achieved 33% growth year-over-year, driven by market share gains and strong surgeon adoption.
Operating Expense Reduction
Total operating expenses decreased by 12% compared to the first quarter of 2024 due to cost-saving measures and headcount reductions.
Progress on Key Pipeline Programs
Significant progress was made on Hyalofast and Cingal, with the second PMA module filed for Hyalofast and alignment achieved with the FDA on the bioequivalence study for Cingal.
ANIK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ANIK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 09, 2025 | $14.74 | $11.64 | -21.03% |
Mar 12, 2025 | $17.11 | $15.21 | -11.10% |
Oct 31, 2024 | $24.68 | $17.11 | -30.67% |
Aug 08, 2024 | $25.68 | $25.68 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Anika Therapeutics (ANIK) report earnings?
Anika Therapeutics (ANIK) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Anika Therapeutics (ANIK) earnings time?
Anika Therapeutics (ANIK) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANIK EPS forecast?
ANIK EPS forecast for the fiscal quarter 2025 (Q2) is -0.26.